CoChat

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

Open access
You, Gihoon, Won, Jonghwa, Lee, Yangsoon, Moon, Dain, Park, Yunji, Lee, Sang Hoon, Lee, Seung-Woo · 2021 · Vaccines
Cited by 48

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential to improve clinical efficacy and safety further. Here, we describe four classes of BsAbs: (a) immune effector cell redirectors; (b) tumor-targeted immunomodulators; (c) dual immunomodulators; and (d) dual tumor-targeting BsAbs. This review describes each of these classes of BsAbs and presents examples of BsAbs in development. We reviewed the biological rationales and characteristics of BsAbs and summarized the current status and limitations of clinical development of BsAbs and strategies to overcome limitations. The field of BsAb-based cancer immunotherapy is growing, and more data from clinical trials are accumulating. Thus, BsAbs could be the next generation of new treatment options for cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines9070724

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 48

Metadata

Authors
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S.-W.
Venue
Vaccines
Publisher
MDPI AG
Published
2021-07-02
Volume
9
Issue
7
Pages
724
ISSN
2076-393X (ISSN-L)
OpenAlex
W3176971136
Cited by
48
References
21
FWCI
4.49
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. https://app.cochat.ai/papers/10.3390/vaccines9070724
The paper
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S.-W. (2021). Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines. https://doi.org/10.3390/vaccines9070724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.